Xeris Biopharma Holdings (XERS) EBT (2020 - 2025)
Historic EBT for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.
- Xeris Biopharma Holdings' EBT rose 10325.78% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7616.47%. This contributed to the annual value of -$57.1 million for FY2024, which is 1007.81% up from last year.
- Xeris Biopharma Holdings' EBT amounted to $621000.0 in Q3 2025, which was up 10325.78% from -$1.9 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBT registered a high of $621000.0 during Q3 2025, and its lowest value of -$50.8 million during Q4 2021.
- In the last 5 years, Xeris Biopharma Holdings' EBT had a median value of -$18.4 million in 2021 and averaged -$18.4 million.
- In the last 5 years, Xeris Biopharma Holdings' EBT tumbled by 13237.41% in 2021 and then skyrocketed by 10325.78% in 2025.
- Over the past 5 years, Xeris Biopharma Holdings' EBT (Quarter) stood at -$50.8 million in 2021, then skyrocketed by 73.88% to -$13.3 million in 2022, then decreased by 2.7% to -$13.6 million in 2023, then soared by 62.48% to -$5.1 million in 2024, then skyrocketed by 112.15% to $621000.0 in 2025.
- Its last three reported values are $621000.0 in Q3 2025, -$1.9 million for Q2 2025, and -$9.2 million during Q1 2025.